Novartis RNA pullback gives biotech stocks whiplash

Novartis stopped short of saying it has given up on RNA therapeutics entirely, but the company's pullback from the sector hurt several public biotechnology firms whose stocks declined in the US based on statements from the Swiss drug maker.